<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">Two intravenous NIs, Peramivir and Zanamivir, are currently undergoing clinical trials [
 <xref ref-type="bibr" rid="CR19">19</xref>]. Laninamivir Octanoate has been evaluated in randomised control trials and have shown good tolerance and efficacy in children aged 9 y and under with Oseltamivir-resistant influenza A (H1N1) virus infection [
 <xref ref-type="bibr" rid="CR23">23</xref>]. Combination therapy is also being evaluated for treatment of severe influenza strains which have likely susceptibility to M2 inhibitors [
 <xref ref-type="bibr" rid="CR19">19</xref>].
</p>
